Oppenheimer raised the firm’s price target on UroGen Pharma (URGN) to $40 from $34 and keeps an Outperform rating on the shares. Zusduri’s Q1 sales of $29.2M vs. the firm/consensus estimates of $22.0M/19.6M together with key launch metrics show strong commercial inflection following the permanent J-code implementation on January 1, the firm says. Management described monthly growth in patient enrollment forms through the quarter with early Q2 maintaining the positive trend, adds Oppenheimer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma reports Q1 EPS (47c), consensus (36c)
- Bancroft Maintains Buy on Zusduri as Commercial Momentum Builds and $35 Price Target Remains Unchanged
- UroGen Pharma: Undervalued Chemoablative Disruptor in NMIBC With Blockbuster Potential by 2030
- UroGen Pharma initiated with a Buy at Jefferies
- UroGen Pharma publishes results from ENVISION trial of Zusduri